We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics".
- Authors
Bovijn, Jonas; Krebs, Kristi; Chen, Chia-Yen; Boxall, Ruth; Censin, Jenny C.; Ferreira, Teresa; Pulit, Sara L.; Glastonbury, Craig A.; Laber, Samantha; Millwood, Iona Y.; Lin, Kuang; Li, Liming; Chen, Zhengming; Milani, Lili; Smith, George Davey; Walters, Robin G.; Mägi, Reedik; Neale, Benjamin M.; Lindgren, Cecilia M.; Holmes, Michael V.
- Abstract
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
- Subjects
SCLEROSTIN; CLINICAL trials; CARDIOVASCULAR diseases risk factors; CARDIOVASCULAR diseases; HUMAN genetics; TRIANGULATION
- Publication
Science Translational Medicine, 2021, Vol 13, Issue 622, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.abf4530